KDM1A and Ewing sarcoma: Very promising preclinical data with HDAC, BET and LSD1 inhibitors have led to inclusion of pediatric Ewing sarcoma patients in early phase clinical trials that are ongoing with these agents (NCT02909777, NCT03600649; NCT03936465).